Management to Present at 9:45 a.m. on the 13th with Breakout Session to Follow
SANTA CLARA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Branislav Vajdic, the Company's Chief Executive Officer, and Vincent Renz, the Company's President, will present at the "OneMedForum 2009" finance conference, to be held January 13-14, 2009, in San Francisco at the Sir Francis Drake Hotel. NewCardio's presentation is scheduled for 9:45 a.m. on the 13th, with a 40-minute breakout session to follow. Management will be available for one-on-one meetings throughout the day.
In addition to the presentations by emerging medtech companies, there will be panels that will address the "drivers and disrupters" affecting each of the following medtech sectors: Orthopedics and Spine; Central Nervous System and Neurostimulation; Cardiology; Urology and Sexual Health; Advances in Surgery; Wound Care; Diagnostics; and, Healthcare Information Technology. These panels will include business development executives as well as venture capitalists who have invested in the eight sectors to be featured. They include: Brook Byers, Kleiner Perkins Caulfield & Byers; Alison de Bord, Alta Partners; David Douglass, Delphi Ventures; Richard Ferrari, De Novo Ventures; Peter Fitzgerald, MD, Latterell Ventures; Fred Middleton, Sanderling Ventures; Teo Forcht Dagi, MD, HLM Venture Partners; and, Jim Shapiro, Kearney Venture Partners. NewCardio will participate in the Cardiology panel.
OneMedPlace is a virtual community of healthcare and life science companies. It has, for the first time, put in place the innovations that will shape the future of health and medicine -- emerging companies and technologies seeking capital, distribution, visibility and resources to help finance, build and grow, and investors and strategic partners looking for health and medical innovations to invest in, acquire, license, distribute, purchase or utilize.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A (No. 2) for the year ended December 31, 2007 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Investor Contact: Hayden IR Jeff Stanlis, VP of Communications (602) 476-1821 firstname.lastname@example.org
|SOURCE NewCardio, Inc.|
Copyright©2009 PR Newswire.
All rights reserved